Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 26, 2021 06:45 ET | Source: TCR2 Therapeutics

TCR² Therapeutics to Participate in Two Upcoming Conferences in June

CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from...
May 13, 2021 06:45 ET | Source: TCR2 Therapeutics

TCR² Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from...
April 29, 2021 06:45 ET | Source: TCR2 Therapeutics

TCR² Therapeutics to Present at the Truist Securities Life Sciences Summit

CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering...
April 10, 2021 08:31 ET | Source: TCR2 Therapeutics

TCR² Highlights Gavo-cel Translational Data and Emerging Solid Tumor Pipeline Preclinical Data at AACR Annual Meeting

CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering...
April 08, 2021 06:45 ET | Source: TCR2 Therapeutics

TCR² Therapeutics to Present at the Needham Healthcare Conference

CAMBRIDGE, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering...
March 29, 2021 08:00 ET | Source: TCR2 Therapeutics

TCR² Therapeutics Establishes Commercial-Scale Cell Therapy Manufacturing Facility

85,000 square foot state-of-the-art facility being built in Rockville, MarylandAccelerates TCR2’s commercial-scale manufacturing timelines with production anticipated in 2023Aaron Vernon hired as Vice...
March 11, 2021 06:45 ET | Source: TCR2 Therapeutics

TCR² Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

- Preliminary safety, efficacy and translational data from gavo-cel Phase 1 trial at AACR 2021 - Preclinical data on autologous CD70 and allogeneic mesothelin TRuC data at AACR 2021 ...
March 10, 2021 16:45 ET | Source: TCR2 Therapeutics

TCR² Presentations at American Association of Cancer Research (AACR) Annual Meeting 2021 to Highlight Solid Tumor Pipeline

CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering...
March 03, 2021 08:00 ET | Source: TCR2 Therapeutics

TCR² Therapeutics to Participate in Two Upcoming Conferences in March

CAMBRIDGE, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering...
February 17, 2021 08:00 ET | Source: TCR2 Therapeutics

TCR² Therapeutics to Present at SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering...